Chemical Structure (Keppra 01)
Keppra Tablet, Film Coated
Product Images NDC 50474-596
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Keppra (NDC 50474-596). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Ucb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Keppra 02)
This appears to be a table showing the percentage of patients taking two different dosages of the medication KEPPRA (1000 mg/day and 3000 mg/day). The table includes three percentages and then shows the percentages for the two groups of patients (N=97 and N=101) taking the respective dosages. There is not enough context to determine what the percentages represent or what condition the medication is being used to treat.*
Figure 2 (Keppra 03)
This appears to be a table or chart with percentages and numbers related to two different dosages of the medication Keppra. However, without more context or information it is difficult to provide a more useful description.*
Figure 3 (Keppra 04)
Figure 4 (Keppra 05)
This text provides data on the percentage of patients in a clinical trial who received either placebo or KEPPRA. The percentage of patients who received KEPPRA was 19.6%, while the percentage who received placebo was 44.6%. The sample sizes for these groups were N=101 and N=7 respectively.*
Figure 5 (Keppra 06)
Figure 6 (Keppra 07)
Principal Display Panel (250 mg Tablet Bottle Label)
This text is a medication label for Levitiracetam, which is being sold under the brand name KEPPRA. The label provides instructions to the pharmacist to dispense the medication in a tight, light-resistant container with a package insert for complete dosage recommendations. Patients must be given an accompanying medication guide. The medication should be stored at 25°C with excursions permitted to 15-30°C. The label provides the product details, including PT# CIP70127 and NDC 50474-594-40 for 120 tablets of 250mg strength. KEPPRA is a trademark of UCB S.A., and the product is manufactured in Smyrna, GA, 30080.*
Principal Display Panel (500 mg Tablet Bottle Label)
This is a medication label for Levitiracetam tablets, with a recommended storage temperature of 25°C (77°F), stored in a tight and light-resistant container with child-resistant closures. The label instructs pharmacists to include a medication guide with each patient's prescription and to refer to the package insert for complete dosage recommendations. The medication is manufactured for UCB, Inc. in Smyrna, GA and is a registered trademark under the name KEPPRA.*
Principal Display Panel (750 mg Tablet Bottle Label)
Principal Display Panel (1000 mg Tablet Bottle Label)
This text describes instructions for dispensing and storing medication in a container with child-resistant closure. It also provides information about the usual dosage and storage conditions for the medication, as well as the manufacturer's details and trademark. The text also includes a PT number and NDC number which may be useful for identification purposes. It recommends dispensing an accompanying Medication Guide to every patient.*
Principal Display Panel (473 mL Bottle Label)
Usual Dosage: See package insert for complete dosage recommendations. This is a 100mg/mL oral solution of levetiracetam manufactured by V.P for bucs, inc. This medication should be dispensed with an accompanying medication guide to each patient. It comes in a 16 fl oz (473 mL) bottle and the pharmacist should dispense it in a tight, light-resistant container with a child-resistant closure. It must be stored at 25°C with some excursions allowed up to 15-30°C. Keep this and all medications out of the reach of children.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
